 SAINT LAURENT, Quebec, Sept. 29, 2021 GLOBE NEWSWIRE -- IntelGenx Corp. TSXV:IGX OTCQB:IGXT IntelGenx today announced that its co-development and commercialization partner for Tadalafil oral films for the treatment of erectile dysfunction ED and benign prostatic hyperplasia BPH the Product, Aquestive Therapeutics, Inc. NASDAQ:AQST Aquestive, has entered into a definitive license and supply agreement the Agreement with an undisclosed leading mens health company. 